Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 6, 2003, Pages 641-650

  Singarayar, Suresh ^a   Bursill, Jane ^a   Wyse, Ken ^a   Bauskin, Asne ^b   Wu, Wan ^b   Vandenberg, Jamie ^a   Breit, Samuel ^b   Campbell, Terence J ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiarrhythmic agents; Arrhythmia; Ion channels; Ischemia; Potassium channels; Proarrhythmia; Transient outward potassium current

Indexed keywords

FLECAINIDE ACETATE; QUINIDINE SULFATE;

ACIDOSIS; ANIMAL CELL; ARTICLE; CHO CELL; DRUG EFFECT; EXTRACELLULAR SPACE; FEMALE; HYPERPOLARIZATION; IC 50; ISCHEMIA; MOLECULAR MODEL; NONHUMAN; PH; POTASSIUM CURRENT; PRIORITY JOURNAL; VOLTAGE CLAMP;

ACIDOSIS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; FLECAINIDE; HYDROGEN-ION CONCENTRATION; ION CHANNEL GATING; MEMBRANE POTENTIALS; MODELS, CARDIOVASCULAR; OVARY; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; QUINIDINE; SENSITIVITY AND SPECIFICITY; SHAL POTASSIUM CHANNELS; STATISTICS; TIME FACTORS;

EID: 0038307015     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.03026.x     Document Type: Article

References (45)

1. Campbell TJ: Proarrhythmic actions of antiarrhythmic drugs: A review. Aust NZ J Med 1990;20:275-282.
2. Roden D, Woosley R, Primm K: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
3. Wyse K, Ye V, Campbell T: Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 1993;21:316-322.
4. The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary report: Effect of encainde and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
5. Echt DS, Liebson PR, Mitchell B, Peters RW, Obias-Manno D, Bearker AH, Arensberg D, Baker A, Friedman L, Green HL, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Suppression Arrhythmia Trial. N Engl J Med 1991;324:781-788.
6. Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA: Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991;68:1551-1555.
7. Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL: Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol 1994;23:283-298.
8. Nattel S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998;37:567-577.
9. Nattel S, Pedersen DH, Zipes DP: Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85.
10. Kou WH, Nelson SD, Lynch JJ, Montgomery DG, DiCarlo L, Lucchesi BR: Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischaemic ventricular fibrillation during the early postmyocardial infarction period: Evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 1987;9:359-365.
11. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium phase 2 reentry? Circulation 1993;87:562-572.
12. Copelan SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomised controlled trials. Circulation 1990;82:1106-1116.
13. Morganroth J, Goin J: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation 1991;84: 1977-1983.
14. Wetherbee DG, Holzman D, Brown MG: Ventricular tachycardia following the administration of quinidine. Am Heart J 1952;43:89-96.
15. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomised controlled trials. JAMA 1993;270:1589-1596.
16. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res 1996;79:659-668.
17. Faivre J-F, Calmels T, Rouanet S, Javre J-L, Cheval B, Bril A: Characterisation of Kv4.3 in HEK293 cells: Comparison with the rat ventricular transient outward potassium current. Cardiovasc Res 1999;41:188-199.
18. Franqueza I, Valenzuela C, Eck J, Tamkun MM, Tamargo J, Snyders DJ: Functional expression of an inactivating potassium channel (Kv4.3) in a mammalian cell line. Cardiovasc Res 1999;41:212-219.
19. Kaah S, Dixon J, Duc J, Ashen D, Nahauer M, Beuckelmann DJ, Steinheck G, McKinnon D, Tomaselli GF: Molecular basis of transient outward potassium current downregulation in heart failure: A decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998;98:1383-1393.
20. Nahauer M, Beuckelmann J, Uherfuhr P, Steinheck G: Regional differences in current density and rate dependent properties of the transient outward current in subepicardial and suhendocardial myocytes of human left ventricle. Circulation 1996;93:168-177.
21. Ks are larger in right than left canine ventricular midmyocardium. Circulation 1999;99:206-210.
22. + current in rat ventricle. Am J Physiol 1999;276:H1599-H1607.
23. Lukas A, Antzelevitch C: Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia: The antiarrhythmic effects of 4-aminopyridine. Cardiovasc Res 1996;32:593-603.
24. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-1666.
25. 2+ in rat and human myocytes. J Physiol 1998;511:827-836.
26. Hulme JT, Orchard CH: Effect of acidosis on transient outward potassium current in isolated rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2000;278:H50-H59.
27. Singarayar S, Singleton C, Tie H, Wyse K, Bursill J, Bauskin A, Wu W, Valenzuela S, Breit S, Campbell T: Effects of components of ischemia on the Kv4.3 current stably expressed in Chinese hamster ovary cells. J Mol Cell Cardiol 2002;34:197-207.
28. Carmeliet E: Cardiac ionic currents and acute ischemia: From channels to arrhythmias. Physiol Rev 1999;79:917-1017.
29. Wang B, Fermini B, Nattel S: Effects of flecainide, quinidine and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 1995;272:184-196.
30. Carmeliet E, Mubagwa K: Antiarrhythmic drugs and cardiac ion channels: Mechanisms of action. Prog Biophys Mol Biol 1998;70:1-72.
31. Agus ZS, Dukes ID, Morad M: Divalent cations modulate the transient outward current in rat ventricular myocytes. Am J Physiol 1991;261:C310-C318.
32. Campbell T, Wyse K, Hemsworth P: Effects of hyperkalemia, acidosis, and hypoxia on the depression of maximum rate of depolarization by class I antiarrhythmic drugs in guinea pig myocardium: Differential actions of class Ib and Ic agents. J Cardiovasc Pharmacol 1991;18:51-59.
33. Nattel S, Elharrar V, Zipes DP, Bailey JC: pH-Dependent electrophysiological effects of quinidine and lidocaine on canine cardiac Purkinje fibres. Circ Res 1981;48:55-61.
34. Grant AO, Trantham JL, Brown KK, Strauss HC: pH-Dependent effects of quinidine on the kinetics of dV/dtmax in guinea pig ventricular myocardium. Circ Res 1982;50:210-217.
35. Hille B: Ionic Channels of Excitable Membranes. Sunderland, MA: Sinauer, 1984, p. 279.
36. Antzelevitch C, Davidenko JM, Sicouri S, Cohen L, Iodice A, Goodrow RJ, Gintant GA: Electrophysiological effects of quinidine in canine Purkinje fibers and ventricular myocardium. Slow development of the antiarrhythmic and arrhythmogenic effects of the drug. In Velasco M, Isreal A, Romero E, Silva H, eds: Recent Advances in Pharmacology and Therapeutics. New York: Excerpta Medica. 1989.
37. + channel. Circ Res 1996;78:1105-1114.
38. Brown TC, Barker GA, Dunlop ME, Loughnan PM: The use of sodium bicarbonate in the treatment of tricyclic antidepressant-induced arrhythmias. Anaesth Intensive Care 1973;1:203-210.
39. Pentel PR, Goldsmith SR, Salerno DM, Nasraway SA, Plummer DW: Effect of hypertonic sodium bicarbonate on encainide overdose. Am J Cardiol 1986;57:878-880.
40. Winkelmann BR, Leinherger H: Life-threatening flecainide toxicity: A pharmacodynamic approach. Ann Intern Med 1987;106:807-814.
41. Salerno DM, Murakami MM, Johnston RB, Keyler DE, Pentel PR: Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs. Am J Emerg Med 1995;13:285-293.
42. Pentel P, Benowitz N: Efficacy and mechanism of action of sodium bicarbonate in the treatment of desipramine toxicity in rats. J Pharmacol Exp Ther 1984;230:12-19.
43. Bou-Abhoud E, Nattel S: Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate. Circulation 1996;94: 1954-1961.
44. An WF, Bowlby MR, Betty M, Cao J, Ling HP, Mendoza G, Hinson JW, Mattsson KI, Strassle BW, Trimmer JS, Rhodes KJ: Modulation of A-type potassium channels by a family of calcium sensors. Nature 2000;403:553-556.
45. Rosati B, Pan Z, Lypen S, Wang HS, Cohen I, Dixon JE, McKinnon D: Regulation of KChIP2 potassium channel beta suhunit gene expression underlies the gradient of transient outward current in canine and human ventricle. J Physiol 2001;533:119-125.